Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 6:16 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 6:16 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $77.73, moving -0.61% from the previous trading session.
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.
Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
These leveraged ETFs won last week despite a broader market bloodbath.
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
by Zacks Equity Research
Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)
by Benjamin Rains
Regeneron Pharmaceuticals, Inc. (REGN) shares have surged 30% in 2020 as investors clamor for stocks that appear immune to the coronavirus economic downturn...
Can Buffett-Style Investing Succeed Today? Stocks & ETFs to Consider
by Neena Mishra
Companies with strong competitive advantage are expected to succeed in this challenging environment.
No Foolin': ADP Report Better than Expected
by Mark Vickery
The ADP headline number came out much better than expected at -27K private sector payroll totals; expectations were for -125K.
ADP Report Better than Expected
by Zacks Equity Research
ADP Report Better than Expected
Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.76, marking a -1.54% move from the previous day.
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Gilead Expands Access to Experimental Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
Sanofi Begins Kevzara Study for Severe Coronavirus Infection
by Zacks Equity Research
Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir
by Zacks Equity Research
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
by Zacks Equity Research
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
How To Play The W-Shaped Recovery
by Daniel Laboe
Patience is the name of the game during market downturns
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.